SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Advanced Micro Devices, Inc. engages in the provision of semiconductor businesses. It operates through the following segments: Data Center, Client, Gaming, and Embedded. The Data Center segment includes server-class CPUs, GPUs, AI accelerators, DPUs, FPGAs, SmartNICs, and Adaptive SoC products. The Client segment refers to the computing platforms, which are a collection of technologies that are designed to work together to provide a more complete computing solution. The Gaming segment is a fundamental component across many products and can be found in APU, GPU, SoC or a combination of a discrete GPU with another product working in tandem. The Embedded segment focuses on the embedded CPUs, GPUs, APUs, FPGAs, and Adaptive SoC products. The company was founded by W. J. Sanders III on May 1, 1969 and is headquartered in Santa Clara, CA.

Advanced Micro Devices Inc.

Advanced Micro Devices Inc

AMD is trending after reports surfaced of potential foundry collaboration with Intel, sparking discussions about the implications for competition and domestic chip manufacturing. The community is weighing the potential benefits and risks of this partnership, with some questioning AMD's motives and others speculating about the broader strategic implications for the semiconductor industry. Bullish sentiment is fueled by anticipation of upcoming earnings and the stock's potential to reach new highs.

Spruce Biosciences, Inc. is a biopharmaceutical company, which engages in developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need. The company was founded on November 13, 2014 and is headquartered in South San Francisco, CA.

Spruce Biosciences Inc

SPRB is trending due to FDA breakthrough therapy designation for its Sanfilippo syndrome treatment, sparking discussions of a potential short squeeze given the stock's low float. The community is actively discussing the news, potential catalysts, and speculating on the stock's next move. Some investors believe the company is significantly undervalued relative to its cash position and pipeline.

Critical Metals Corp. engages in the mining, exploration, and development of lithium metals. It owns Wolfsberg Project and Tanbreez Project. The company was founded on October 24, 2022 and is headquartered in British Virgin Islands.

Critical Metals Corp.

CRML is trending amid speculation of a potential U.S. government stake in the company's Greenland rare earths mine, fueled by recent news reports. The community is discussing the potential for a short squeeze and comparing CRML to other government-backed plays. Investors are closely watching the stock's movements and anticipating further news or official confirmation.

GraniteShares ETF Trust - GraniteShares 2x Long AMD Daily ETF

GraniteShares 2x Long AMD Daily ETF

GraniteShares 2x Long AMD Daily ETF ($AMDL) is trending as traders discuss recent volatility in AMD, with some expressing frustration over perceived market manipulation. The community is weighing bullish sentiment and potential opportunities for explosive gains against concerns about overnight losses and the ETF's leveraged nature. Some traders are considering AMD's potential as an AI play and anticipating upcoming earnings.

Alchemy Pay

Alchemy Pay (ACH) is trending as the community discusses its potential, especially around real-world applications and partnerships. Recent news focuses on expanded fiat on-ramps and regulatory approvals, generating speculation about future growth. Community members are actively debating price predictions and entry points, with some expressing frustration over past performance.

Aduro Clean Technologies, Inc. engages in the manufacture of oils and specialty chemicals using waste plastics. It focuses on hydrochemolytic technology to transform post-consumer polymer waste into a resource for the circular economy. It also develops a novel chemical conversion process to transform waste plastics and low grade renewable oils into renewable fuels and specialty chemicals. The company was founded on January 10, 2018 by Ofer Vicus and William Marcus Trygstad and is headquartered in Sarnia, Canada.

Aduro Clean Technologies Inc

Aduro Clean Technologies is trending as the company progresses toward commissioning its pilot plant in September, a key milestone for its Hydrochemolytic technology which transforms waste into valuable resources. Community members are closely watching for updates on partnerships and the potential impact of upcoming PR campaigns. Bullish sentiment is fueled by the company's expansion into new markets like synthetic turf recycling and its collaborations within the plastics industry.

ADMA Biologics, Inc. operates as a biopharmaceutical company, which is engaged in manufacturing, marketing, and developing specialty plasma-derived biologics. The firm operates through the following business segments: ADMA BioManufacturing, Plasma Collection Center, and Corporate. The ADMA BioManufacturing segment consists of immune globulin manufacturing and development operations. The Plasma Collection Center consists of source plasma collection facilities. The Corporate segment includes general and administrative overhead expenses. The company was founded by Adam S. Grossman and Jerrold B. Grossman on June 24, 2004 and is headquartered in Ramsey, NJ.

Adma Biologics Inc

Qfin Holdings, Inc. is a holding company, which engages in the provision of AI-empowered Credit-Tech platform. It provides comprehensive suite of technology services to assist financial institutions and consumers and SMEs in the loan lifecycle, ranging from borrower acquisition, preliminary credit assessment, fund matching and post-facilitation services. It is dedicated to making credit services more accessible and personalized to consumers and SMEs through Credit-Tech services to financial institutions. The company was founded on July 25, 2016 and is headquartered in Shanghai, China.

Qfin Holdings Inc. - ADR

Qifu Technology Inc - ADR

Verizon Communications, Inc. is a holding company, which engages in the provision of communications, information, and entertainment products and services. It operates through the Consumer and Business segments. The Consumer segment provides consumer-focused wireless and wire line communications services and products. The Business segment offers wireless and wireline communications services and products, including FWA broadband, data, video and conferencing services, corporate networking solutions, security and managed network services, local and long-distance voice services, and network access to deliver various IoT services and products. The company was founded in 1983 and is headquartered in New York, NY.

Verizon Communications Inc

Verizon Communications Inc.

Verizon is trending as investors discuss its upcoming ex-dividend date and potential earnings beat, while also evaluating its competitive position against peers like T-Mobile and AT&T. Community members are weighing the stock's value as a dividend play amidst concerns about subscriber growth and overall sector performance. Reports that Trump may switch from AT&T due to poor service has also stirred speculation about whether VZ stands to benefit.

Sanmina Corp. engages in the provision of integrated manufacturing solutions, components, products and repair, logistics and after-market services. It operates through the following segments: Integrated Manufacturing Solutions (IMS) and Components, Products and Services (CPS). The IMS segment consists of printed circuit board assembly and test, final system assembly and test and direct-order-fulfillment. The CPS segment includes interconnect systems and mechanical systems. The company was founded by Jure Sola in 1980 and is headquartered in San Jose, CA.

Sanmina Corp

Sanmina ($SANM) is trending due to better-than-expected earnings, which beat analyst expectations. Community members are discussing the company's growth prospects and potential for continued momentum, as well as the possibility for stock price appreciation. The stock is also getting attention as a momentum pick in various portfolios.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

$ACST.DL1224 &#39;42.2% reduction in triglyceride levels among patients receiving CaPre while on background statin therapy at 12 weeks&#39;...This blows AMRN out of the water.These people didn&#39;t have the placebo in their systems to see these kinds of results...Stay tuned!

Lawrence Valure

(e)Quanimus Investments

Joey Tokes

Mr. Mysterious

Oveja Bohemia

Stocks Investor

STARlab

StockTwits for iOS

StockTwits Web

Acasti Pharma Inc

$ACST '42.2% reduction in triglyceride levels among patients receiving CaPre while on background statin therapy at 12 weeks'...This blows AMRN out of the water.These people didn't have the placebo in their systems to see these kinds of results...Stay tuned!

glen philippe

I should&#39;ve added,we are better when adding the probable Secondary Endpoints...The Primary is basically the same as Vascepa,at 45%...We just used a different placebo to match up against,for whatever reason...If everything else plays out like this,it will only be the placibo that remains the problem and not the drug itself...The FDA will have to address that as possibly being their fault.You have to match both drugs against the same placibo for any trial to matter.Otherwise one drug has a possible advantage over the other,such as this time.

Alex

I should've added,we are better when adding the probable Secondary Endpoints...The Primary is basically the same as Vascepa,at 45%...We just used a different placebo to match up against,for whatever reason...If everything else plays out like this,it will only be the placibo that remains the problem and not the drug itself...The FDA will have to address that as possibly being their fault.You have to match both drugs against the same placibo for any trial to matter.Otherwise one drug has a possible advantage over the other,such as this time.

Imo,the placebo data may get thrown out if this continues in the 2nd arm,and they&#39;ll use the data that Amarin used for their placebo,as the FDA is involved in the planning of the trials.,,The rest of the results are outstanding.

Imo,the placebo data may get thrown out if this continues in the 2nd arm,and they'll use the data that Amarin used for their placebo,as the FDA is involved in the planning of the trials.,,The rest of the results are outstanding.

@robinandthe7hoods what exact data of the reduce it trial are you claiming acst will be able to use as their data? I&#39;m gonna go with 0. Acst cannot use data from another trial for their p3. Capre and vascepa are 2 different drugs...the data does not transfer which is why capre was hoping to use the strength data but that hope is gone now.

Valentin

StockTwits For Android 

 what exact data of the reduce it trial are you claiming acst will be able to use as their data? I'm gonna go with 0. Acst cannot use data from another trial for their p3. Capre and vascepa are 2 different drugs...the data does not transfer which is why capre was hoping to use the strength data but that hope is gone now.

Matt Jones

@robinandthe7hoods You really don&#39;t understand why a placebo is used do you?? The placebo was inert that&#39;s why the effect was only witnessed at 5 out of 54 sites.  You cant claim a  42% reduction for CAPre if those that were not taking it had a 30% improvement. Hence the need for an investigation because if they can&#39;t show  that the placebo group were either not given a placebo or took something other than the placebo then the result as it stands is correct

 You really don't understand why a placebo is used do you?? The placebo was inert that's why the effect was only witnessed at 5 out of 54 sites.  You cant claim a  42% reduction for CAPre if those that were not taking it had a 30% improvement. Hence the need for an investigation because if they can't show  that the placebo group were either not given a placebo or took something other than the placebo then the result as it stands is correct